JP2016535772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535772A5 JP2016535772A5 JP2016551466A JP2016551466A JP2016535772A5 JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5 JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- hydrogen atom
- methyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013232571 | 2013-11-08 | ||
| JP2013232571 | 2013-11-08 | ||
| JP2014128562 | 2014-06-23 | ||
| JP2014128562 | 2014-06-23 | ||
| PCT/JP2014/080005 WO2015068856A1 (en) | 2013-11-08 | 2014-11-05 | Pyrazole for the treatment autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535772A JP2016535772A (ja) | 2016-11-17 |
| JP2016535772A5 true JP2016535772A5 (enExample) | 2017-09-21 |
| JP6412148B2 JP6412148B2 (ja) | 2018-10-24 |
Family
ID=51999482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551466A Active JP6412148B2 (ja) | 2013-11-08 | 2014-11-05 | 自己免疫疾患治療のためのピラゾール |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9321757B2 (enExample) |
| EP (1) | EP3066094B1 (enExample) |
| JP (1) | JP6412148B2 (enExample) |
| CN (1) | CN105899505B (enExample) |
| BR (1) | BR112016010041B1 (enExample) |
| CA (1) | CA2929316C (enExample) |
| EA (1) | EA201690952A1 (enExample) |
| ES (1) | ES2777123T3 (enExample) |
| TW (1) | TW201605847A (enExample) |
| UY (1) | UY35821A (enExample) |
| WO (1) | WO2015068856A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN105899505B (zh) * | 2013-11-08 | 2018-08-28 | 武田药品工业株式会社 | 用于治疗自身免疫病症的吡唑 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN108473501B (zh) * | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 治疗化合物、其组合物及使用方法 |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| CN106317952B (zh) * | 2016-08-19 | 2018-03-09 | 福建中烟工业有限责任公司 | 一种增白组合物、其制备方法及用途 |
| JP2019196309A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| EP4212523A1 (en) * | 2016-10-26 | 2023-07-19 | Rigel Pharmaceuticals, Inc. | Pyrazole amide compounds as irak inhibitors |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
| BR112019024322A2 (pt) | 2017-05-22 | 2020-06-16 | F. Hoffmann-La Roche Ag | Compostos e composições terapêuticos e métodos de uso dos mesmos |
| EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND USES OF SUCH |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| CN112236429B (zh) * | 2018-04-05 | 2024-10-11 | 默克专利有限公司 | 用作ii型irak抑制剂的杂芳基化合物及其用途 |
| EP3553061A1 (en) * | 2018-04-12 | 2019-10-16 | Centre National De La Recherche Scientifique (Cnrs) | New inhibitors of bone resorption |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| TWI898556B (zh) | 2018-07-13 | 2025-09-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| CA3224985A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| KR102625224B1 (ko) | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP4054573A1 (en) * | 2019-11-05 | 2022-09-14 | Dermira, Inc | Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CA3186630A1 (en) * | 2020-06-30 | 2022-01-06 | Dermira, Inc. | Irak4 inhibitors and topical uses thereof |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2023183377A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008526723A (ja) * | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| US9206142B2 (en) * | 2006-10-31 | 2015-12-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
| EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| CN102933572B (zh) * | 2010-04-07 | 2015-01-07 | 霍夫曼-拉罗奇有限公司 | 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法 |
| CN105899505B (zh) * | 2013-11-08 | 2018-08-28 | 武田药品工业株式会社 | 用于治疗自身免疫病症的吡唑 |
-
2014
- 2014-11-05 CN CN201480072420.9A patent/CN105899505B/zh active Active
- 2014-11-05 EA EA201690952A patent/EA201690952A1/ru unknown
- 2014-11-05 EP EP14805371.3A patent/EP3066094B1/en active Active
- 2014-11-05 ES ES14805371T patent/ES2777123T3/es active Active
- 2014-11-05 JP JP2016551466A patent/JP6412148B2/ja active Active
- 2014-11-05 CA CA2929316A patent/CA2929316C/en active Active
- 2014-11-05 WO PCT/JP2014/080005 patent/WO2015068856A1/en not_active Ceased
- 2014-11-05 BR BR112016010041-7A patent/BR112016010041B1/pt active IP Right Grant
- 2014-11-05 UY UY0001035821A patent/UY35821A/es not_active Application Discontinuation
- 2014-11-05 US US14/533,326 patent/US9321757B2/en active Active
- 2014-11-05 TW TW103138324A patent/TW201605847A/zh unknown
-
2016
- 2016-04-25 US US15/137,161 patent/US9890145B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535772A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2016536363A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2016540811A5 (enExample) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| JP2017513894A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| JP2016536364A5 (enExample) | ||
| JP2015501799A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2010506825A5 (enExample) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| JP2016537389A5 (enExample) | ||
| JP2016530322A5 (enExample) | ||
| JP2013531074A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2015535851A5 (enExample) | ||
| JP2020500916A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2016529235A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| JP2017520540A5 (enExample) | ||
| JP2017519818A5 (enExample) |